NasdaqGM:AXSMPharmaceuticals
Is Axsome Therapeutics (AXSM) Using Solriamfetol’s Phase 3 ADHD Trial To Redefine Its CNS Strategy?
Axsome Therapeutics has recently dosed the first patient in its FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled trial of solriamfetol in adolescents aged 12 to under 18 years with ADHD, assessing six-week changes in ADHD-RS-5 total scores across approximately 468 participants.
This study extends solriamfetol’s development beyond sleep-related conditions into adolescent ADHD, underlining Axsome’s push to broaden its CNS treatment footprint across multiple indications.
We’ll now...